Department of Rheumatology and Clinical Immunology, Key Laboratory of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Ministry of Education, Beijing, China.
Department of Rheumatology, General Hospital of Tianjin Medical University, Tianjin, China.
Arthritis Res Ther. 2018 Sep 24;20(1):214. doi: 10.1186/s13075-018-1712-y.
The diagnosis of Behçet's disease (BD) remains challenging due to the lack of diagnostic biomarkers. This study aims to identify potential serum metabolites associated with BD and its disease activity.
Medical records and serum samples of 24 pretreated BD patients, 12 post-treated BD patients, and age-matched healthy controls (HC) were collected for metabolomics and lipidomics profiling using UPLC-QTOF-MS and UPLC-QTOF-MS approaches. Additionally, serum samples from an independent cohort of BD patients, disease controls including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Takayasu's arteritis (TA), Crohn's disease (CD) patients, and HC were collected for further validation of two potential biomarkers using UPLC-QTOFMS analysis.
Unsupervised principal component analysis (PCA) showed a clear separation of metabolomics profiles of BD patients from HC. Statistical analysis of the data revealed differential metabolites between BD patients and HC. The serum levels of some phosphatidylcholines (PCs) were found to be significantly lower in BD patients, while the levels of several polyunsaturated fatty acids (PUFAs) were increased markedly in the BD group compared with HC. Furthermore, the serum level of two omega-6 PUFAs, linoleic acid (LA) and arachidonic acid (AA), were dramatically decreased in patients with remission. A validation cohort confirmed that the serum LA and AA levels in BD patients were significantly higher than those in HC and patients with RA, SLE, TA, and CD. In addition, receiver operating characteristic (ROC) analysis indicated good sensitivity and specificity.
The serum metabolomics profiles in BD patients are altered. Serum LA and AA are promising diagnostic biomarkers for BD.
由于缺乏诊断生物标志物，Behçet 病（BD）的诊断仍然具有挑战性。本研究旨在确定与 BD 及其疾病活动相关的潜在血清代谢物。
收集了 24 例预处理 BD 患者、12 例治疗后 BD 患者和年龄匹配的健康对照者（HC）的病历和血清样本，采用 UPLC-QTOF-MS 和 UPLC-QTOF-MS 方法进行代谢组学和脂质组学分析。此外，还收集了来自 BD 患者独立队列的血清样本、疾病对照者（包括类风湿关节炎（RA）、系统性红斑狼疮（SLE）、大动脉炎（TA）、克罗恩病（CD）患者）和 HC 的血清样本，采用 UPLC-QTOFMS 分析进一步验证了两个潜在生物标志物。
无监督主成分分析（PCA）显示 BD 患者的代谢组学图谱与 HC 明显分离。对数据的统计分析显示，BD 患者与 HC 之间存在差异代谢物。与 HC 相比，BD 患者的某些磷脂（PC）血清水平明显降低，而多不饱和脂肪酸（PUFA）的水平则显著升高。此外，缓解期患者的两种 ω-6 PUFAs，亚油酸（LA）和花生四烯酸（AA）的血清水平显著降低。验证队列证实，BD 患者的血清 LA 和 AA 水平明显高于 HC 和 RA、SLE、TA 和 CD 患者。此外，ROC 分析表明具有良好的敏感性和特异性。
BD 患者的血清代谢组学图谱发生改变。血清 LA 和 AA 是 BD 的有前途的诊断生物标志物。
Zotero 插件
